Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (3) , 419-424
Abstract
No abstract availableKeywords
Funding Information
- Ministero della Salute (2018–105/01)
- Gilead Sciences
- AbbVie
- GlaxoSmithKline
- Meso Scale Diagnostics
This publication has 24 references indexed in Scilit:
- Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapyExpert Opinion on Biological Therapy, 2014
- Prospective long‐term study of hepatitis B virus reactivation in patients with hematologic malignancyJournal of Gastroenterology and Hepatology, 2014
- Management of patients with hepatitis B who require immunosuppressive therapyNature Reviews Gastroenterology & Hepatology, 2013
- Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective studyHepatology, 2013
- Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis BJournal of Clinical Oncology, 2013
- Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicityVaccine, 2012
- Rituximab-Associated InfectionsSeminars in Hematology, 2010
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Statements from the Taormina expert meeting on occult hepatitis B virus infectionJournal of Hepatology, 2008
- Prophylaxis and treatment of hepatitis B in immunocompromised patientsDigestive and Liver Disease, 2007